Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Tenet Healthcare (THC) Benefiting from Capital Return Potential, Says Wells Fargo
Tenet Healthcare (THC) Benefiting from Capital Return Potential, Says Wells Fargo
Rizwan Siddiqui
Tue, February 24, 2026 at 3:23 PM GMT+9 2 min read
In this article:
THC
+1.68%
Tenet Healthcare Corporation (NYSE:THC) is among the 15 Undervalued Momentum Stocks That Are Taking Off.
Following Tenet Healthcare Corporation’s (NYSE:THC) Q4 update, Wells Fargo lifted its target from $229 to $265 and maintained its Overweight rating on February 16. The firm noted that the investor reaction after the Q4 results was somewhat “surprising,” given that EBITDA had been largely pre-announced and guidance had come in broadly in line with expectations. The stock had rallied 17% after the company announced Q4 results on February 11.
According to Wells Fargo, the strong move was not due to incremental earnings revisions, but rather to improving investor conviction around capital return potential and Tenet’s alignment with prevailing market narratives, which “appear to be important drivers.”
Tenet Healthcare (THC) Benefiting from Capital Return Potential, Says Wells Fargo
Jirsak / shutterstock.com
In its Q4 update on February 11, the company reported revenue of $5.53 billion, 1% above the consensus of $5.47 billion. Adjusted EPS grew 37% year over year and came in at $4.70, which was ahead of the street expectation of $4.05. For FY 2026, the company guided for revenue of $21.5-$22.3 billion and adjusted EBITDA of $4.485-$4.785 billion. EPS for the year is expected to be in the range of $16.19-$18.47, which was again ahead of the consensus of $16.46 at the mid-point.
Several other analysts raised their price targets after the results. Among them, Morgan Stanley raised its price target to $260 from $247, RBC Capital to $277 from $253, and KeyBanc to $250 from $225.
After strong 57% returns in 2025, the stock has rallied another 16% so far in 2026. At $230, the stock currently trades close to its 52-week high of $235.8, as of February 20.
While we acknowledge the potential of THC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Software Infrastructure Stocks to Buy According to Hedge Funds and Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy
Privacy Dashboard
More Info